OncLive TV

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the need to develop novel therapies in chronic lymphocytic leukemia.

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Joseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Reema A. Patel, MD, discusses ongoing research efforts in pancreatic cancer.

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

Reema A. Patel, MD, discusses findings from the NAPOLI-1 trial in pancreatic cancer.

Pashtoon M. Kasi, MD, MS, ​discusses findings from the CRC-MRD Consortia in colorectal cancer.

Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.